Modified AAV Capsids Enhance Retinal Cell Tropism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral vectors for gene therapy, particularly adeno-associated virus (AAV) vectors, face challenges in optimizing cell tropism and delivery to specific tissues like the retina, limiting their effectiveness in treating ocular diseases.
Innovation Solution
Modified AAV capsid proteins, such as AAV2.5T/7m8, with specific amino acid modifications that enhance heparan sulfate binding and tropism, allowing for improved delivery and transduction of retinal cells when administered intravitreally.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If wild-type AAV vectors are used for gene delivery, then broad tissue tropism is achieved, but specific delivery to retinal cells is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific amino acid modifications at particular locations on the AAV capsid protein (e.g., residues 576-581 in Loop IV) to enhance binding to heparan sulfate proteoglycans. This localized modification strategy allows the capsid to maintain its general function while acquiring enhanced specificity for retinal cell delivery through targeted changes in the heparan sulfate binding region.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid sequences in the capsid protein, particularly in the heparan sulfate binding region. By changing specific amino acid parameters (substitutions, deletions, insertions) in Loop IV and other regions, the invention optimizes the capsid's affinity for heparan sulfate, thereby improving retinal cell targeting while maintaining overall capsid stability and function.
2Ease of operation
If AAV vectors are administered intravitreally, then direct retinal delivery is achieved, but infectivity and transduction efficiency are limited
Solution Approach 1:
The patent applies parameter changes by modifying amino acid residues in the capsid protein to enhance heparan sulfate binding affinity. Specific substitutions (e.g., K576R, K579R), deletions (e.g., Δ576-581), and insertions in Loop IV alter the capsid's chemical properties, increasing its ability to bind heparan sulfate proteoglycans on retinal cell surfaces, thereby improving transduction efficiency following intravitreal administration.
Solution Approach 2:
The patent creates composite capsid structures by combining wild-type AAV capsid regions with modified sequences that have enhanced heparan sulfate binding properties. These chimeric capsids integrate beneficial features from different AAV serotypes or engineered sequences, resulting in a composite structure that maintains overall capsid integrity while acquiring improved retinal cell targeting and transduction capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified capsid proteins enable increased infectivity and altered tropism of AAV vectors, enabling more efficient and targeted gene delivery to retinal cells, potentially leading to enhanced therapeutic outcomes for ocular diseases.
Implementation Method 1
amino acid modifications that enhance heparan sulfate binding and tropism
Data Source
AI summary
The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein that binds heparan sulfate proteoglycans, where the AAV virions exhibit greater infectivity of retinal cells, altered tropism and/or the ability to bind and cross the inner limiting membrane following intravitreal injection. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.